Management of acute severe colitis

Area of Science:

• Gastroenterology and Immunology
• Inflammatory Bowel Disease (IBD) Research

Background:

• Acute severe colitis requires early identification for prompt intervention.
• Corticosteroids have been the primary treatment since 1955.
• Ciclosporin has decreased early colectomy rates, but up to 30% of patients still require colectomy.

Purpose of the Study:

• To review the current management of acute severe colitis.
• To highlight the impact of medical advancements on patient outcomes.
• To discuss future therapeutic directions in IBD treatment.

Main Methods:

• Review of historical and current treatment strategies for acute severe colitis.
• Analysis of colectomy rates and mortality in the context of evolving medical management.
• Discussion of pharmacological advancements and their clinical implications.

Main Results:

• Mortality rates have significantly decreased to less than 1% in specialist centers, a stark contrast to the 30% in the pre-steroid era.
• Despite modern medical interventions, a substantial proportion of patients (up to 30%) still necessitate colectomy during the same hospital admission.
• The introduction of ciclosporin has been instrumental in reducing the need for early colectomies.

Conclusions:

• Modern medical management has dramatically improved survival rates for acute severe colitis.
• Further therapeutic innovations targeting the core inflammatory processes are anticipated.
• The ongoing evolution of treatment strategies aims to further reduce colectomy rates and improve long-term patient outcomes in IBD.